DK3544584T3 - Farmaceutisk parenteral formulering indeholdende cargluminsyre - Google Patents

Farmaceutisk parenteral formulering indeholdende cargluminsyre Download PDF

Info

Publication number
DK3544584T3
DK3544584T3 DK17800854.6T DK17800854T DK3544584T3 DK 3544584 T3 DK3544584 T3 DK 3544584T3 DK 17800854 T DK17800854 T DK 17800854T DK 3544584 T3 DK3544584 T3 DK 3544584T3
Authority
DK
Denmark
Prior art keywords
formulation containing
parenteral formulation
carglumic acid
pharmaceutical parenteral
containing carglumic
Prior art date
Application number
DK17800854.6T
Other languages
English (en)
Inventor
Fabio Berlati
Sergio Menegon
Pierluigi Farina
Diego Provvedini
Marco Barchielli
Alberto Mattei
Original Assignee
Recordati Ind Chimica E Farmaceutica S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati Ind Chimica E Farmaceutica S P A filed Critical Recordati Ind Chimica E Farmaceutica S P A
Application granted granted Critical
Publication of DK3544584T3 publication Critical patent/DK3544584T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK17800854.6T 2016-11-22 2017-11-20 Farmaceutisk parenteral formulering indeholdende cargluminsyre DK3544584T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16199942.0A EP3323410A1 (en) 2016-11-22 2016-11-22 Pharmaceutical parenteral formulation containing carglumic acid
PCT/EP2017/079738 WO2018095848A1 (en) 2016-11-22 2017-11-20 Pharmaceutical parenteral formulation containing carglumic acid

Publications (1)

Publication Number Publication Date
DK3544584T3 true DK3544584T3 (da) 2020-11-23

Family

ID=57389297

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17800854.6T DK3544584T3 (da) 2016-11-22 2017-11-20 Farmaceutisk parenteral formulering indeholdende cargluminsyre

Country Status (20)

Country Link
US (1) US11103474B2 (da)
EP (2) EP3323410A1 (da)
JP (1) JP6942182B2 (da)
KR (1) KR102459213B1 (da)
AU (1) AU2017364135B2 (da)
BR (1) BR112019009848A2 (da)
CA (1) CA3040018A1 (da)
CO (1) CO2019003876A2 (da)
DK (1) DK3544584T3 (da)
EA (1) EA039003B1 (da)
ES (1) ES2837804T3 (da)
HR (1) HRP20201696T1 (da)
HU (1) HUE052207T2 (da)
IL (1) IL266755B (da)
LT (1) LT3544584T (da)
MX (1) MX2019005775A (da)
PT (1) PT3544584T (da)
RS (1) RS61184B1 (da)
SI (1) SI3544584T1 (da)
WO (1) WO2018095848A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200368192A1 (en) 2019-05-22 2020-11-26 Recordati S.P.A. Treatment of hyperammonemia in patients with renal insufficiency
WO2020239882A1 (en) 2019-05-30 2020-12-03 Recordati Industria Chimica E Farmaceutica S.P.A. Pharmaceutical formulation for carglumic acid
CN111407754A (zh) * 2020-04-07 2020-07-14 中国科学院深圳先进技术研究院 卡谷氨酸在制备预防和治疗冠状病毒的药物中的应用
US11628143B1 (en) 2022-06-14 2023-04-18 Novitium Pharma LLC Tablet for oral suspension
CN115770225A (zh) * 2022-11-25 2023-03-10 远大医药(中国)有限公司 一种卡谷氨酸冻干固体制剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1112347A (en) * 1965-08-20 1968-05-01 Pierre Wirth Salts of organic bases with n-carbamyl-l-glutamic acid
US5056246A (en) * 1989-10-27 1991-10-15 Nikolaus Balonier Device for taking trousers off an ironing machine
EP1838353A2 (en) 2005-01-21 2007-10-03 Introgen Therapeutics, Inc. Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic acids
ES2968301T3 (es) * 2008-08-05 2024-05-08 Wyeth Llc Liofilización por encima del colapso
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
US10064826B2 (en) 2013-03-15 2018-09-04 Navinta, Llc Direct compression and dry granulation processes for preparing carglumic acid tablets having less impurities than those produced by wet granulation process
CN105056246A (zh) 2015-08-18 2015-11-18 武汉武药科技有限公司 一种卡谷氨酸固体组合物及其制备方法

Also Published As

Publication number Publication date
AU2017364135B2 (en) 2023-06-15
EP3544584A1 (en) 2019-10-02
US20190282526A1 (en) 2019-09-19
EA201991023A1 (ru) 2019-12-30
EA039003B1 (ru) 2021-11-19
RS61184B1 (sr) 2021-01-29
IL266755A (en) 2019-07-31
JP6942182B2 (ja) 2021-09-29
AU2017364135A1 (en) 2019-04-18
ES2837804T3 (es) 2021-07-01
PT3544584T (pt) 2020-10-29
KR20190086662A (ko) 2019-07-23
CO2019003876A2 (es) 2019-06-28
IL266755B (en) 2022-01-01
SI3544584T1 (sl) 2020-12-31
EP3323410A1 (en) 2018-05-23
WO2018095848A1 (en) 2018-05-31
MX2019005775A (es) 2019-08-12
BR112019009848A2 (pt) 2019-08-20
HRP20201696T1 (hr) 2020-12-25
HUE052207T2 (hu) 2021-04-28
JP2019535736A (ja) 2019-12-12
AU2017364135A2 (en) 2019-05-02
KR102459213B1 (ko) 2022-10-27
CA3040018A1 (en) 2018-05-31
LT3544584T (lt) 2021-01-11
US11103474B2 (en) 2021-08-31
EP3544584B1 (en) 2020-09-16

Similar Documents

Publication Publication Date Title
DK3529248T3 (da) Farmaceutiske sammensætninger
DK3236943T3 (da) Sammensætninger til ileo-jejunal lægemiddeladministration
DK3479819T3 (da) Stabilt væskeformigt farmaceutisk præparat
DK3089741T3 (da) Farmaceutiske sammensætninger omfattende azd9291
BR112016026879A2 (pt) Composição farmacêutica líquida
DK3529240T3 (da) Farmaceutiske forbindelser
DK3532029T3 (da) Flydende farmaceutisk sammensætning
DK3634377T3 (da) Farmaceutisk formulering
BR112017027227A2 (pt) Agente anti-câncer
DK3544584T3 (da) Farmaceutisk parenteral formulering indeholdende cargluminsyre
DK3380146T3 (da) Medikamentadministrationsanordning
DK3821905T3 (da) Insulin indeholdende farmaceutiske sammensætninger
DK3145488T3 (da) Flydende farmaceutiske forbindelse
DK3199161T3 (da) Farmaceutisk præparat
MA43705A (fr) Formulation pharmaceutique
DK3463345T3 (da) Farmaceutiske kombinationer
DK3278801T3 (da) Farmaceutisk sammensætning indeholdende mirabegron
IL266537A (en) pharmaceutical preparation
DK3280447T3 (da) Farmaceutiske formuleringer
ZA201807851B (en) Pharmaceutical formulation
DK3256154T3 (da) Farmaceutisk formulering omfattende antistof
DK3601277T3 (da) Farmaceutisk formulering
GB201506755D0 (en) Novel pharmaceutical formulation
DK3288967T3 (da) Farmaceutisk forbindelse
DK3089740T3 (da) Farmaceutisk sammensætning